Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GW870086X

Known as: GW870086 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Steroids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Cytokine-Induced Loss of Glucocorticoid Function: Effect of Kinase Inhibitors, Long-Acting β2-Adrenoceptor Agonist and Glucocorticoid Receptor Ligands
Acting on the glucocorticoid receptor (NR3C1), glucocorticoids are widely used to treat inflammatory diseases. However… Expand
2015
2015
Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials
Topical corticosteroids remain the first-line therapy for atopic dermatitis (AD). Hence, we investigated the efficacy and safety… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2015
2015
The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma.
 
2015
2015
Correction: Cytokine-Induced Loss of Glucocorticoid Function: Effect of Kinase Inhibitors, Long-Acting β2-Adrenoceptor Agonist and Glucocorticoid Receptor Ligands
There is an error in the title. The correct title is: Cytokine-Induced Loss of Glucocorticoid Function: Effect of Kinase… Expand
2015
2015
A new case of Fas-associated death domain protein deficiency and update on treatment outcomes.
In this study, we demonstrated that GW870086X inhibited the bronchoconstrictor response to inhaledAMPchallenge after both a… Expand
  • figure 2
  • figure 1
  • figure 2
2013
2013
Discovery of GW870086: a potent anti‐inflammatory steroid with a unique pharmacological profile
Glucocorticoids are highly effective therapies for a range of inflammatory diseases. Advances in the understanding of the diverse… Expand
2013
2013
Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial
Abstract Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086, which has… Expand
2013
2013
Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X.
PURPOSE Glucocorticoid (GC)-induced glaucoma is an undesirable side effect of traditional GCs. Ocular hypertension responsible… Expand
2013
2013
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies
 
2013
2013
Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE